Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in a Phase ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

Read More: mRNA Technology Gave Us the First COVID-19 Vaccines.It Could Also Upend the Drug Industry. Both companies are targeting the four flu strains that the World Health Organization (WHO ...

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

The wait for mRNA flu vaccines in a pandemic could be months shorter than what we experienced in 2020. Related: Flu activity gaining steam in the U.S. as vaccination rates lag But ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...